FDA Submission for Finerenone by Macleods Pharmaceuticals
Macleods Pharmaceuticals has submitted an ANDA for Finerenone, currently under review.
Asset / Drug
Drug and asset intelligence for Finerenone with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Mineralocorticoid Receptor Antagonist
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.